cas 15911-75-8|| where to buy L-Norvaline, 1,1-dimethylethyl ester

Produktname:L-Norvaline, 1,1-dimethylethyl ester

IUPAC Name:tert-butyl (2S)-2-aminopentanoate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM599730-1g	in stock	ưưȺ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 15911-75-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:15911-75-8; Molekulare Formel:C9H19NO2; Schmelzpunkt:-; SMILES-Code:CCC[C@H](N)C(=O)OC(C)(C)C; Dichte:

: Katalognummer:CM599730; Molekulargewicht:173.26; Siedepunkt:; Mdl-Nr.:MFCD07368844; Lagerung:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Ogsiveo; The FDA has approved Ogsiveo (Nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. The FDA approval of Ogsiveo is based on the results from the Phase 3 DeFi trial. The results showed that Ogsiveo met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Ogsiveo is an oral, selective, small molecule gamma secretase inhibitorγ. Gamma secretase cleaves multiple transmembrane proteins, including Notch, that are believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.